Related references
Note: Only part of the references are listed.Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients
C. Braconi et al.
ANNALS OF ONCOLOGY (2008)
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Jayne M. Stommel et al.
SCIENCE (2007)
Pediatric KIT-wild-type and platelet-derived growth factor receptor α-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors
Katherine A. Janeway et al.
CANCER RESEARCH (2007)
Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse
Rachael Natrajan et al.
CANCER RESEARCH (2006)
Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor
Jonathan C. Trent et al.
CANCER (2006)
Interaction of IGF signaling and the androgen receptor in prostate cancer progression
Jennifer D. Wu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
Leonardo A. Meza-Zepeda et al.
CANCER RESEARCH (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Transcriptional regulation of the insulin-like growth factor-1 receptor gene in breast cancer
Rive Sarfstein et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2006)
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms
Chi Tarn et al.
CANCER RESEARCH (2006)
Blockade of IGF-1 receptor tyrosine kinase has antlineoplastic effects in hepatocellular carcinoma cells
M Höpfner et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours
M Höpfner et al.
ENDOCRINE-RELATED CANCER (2006)
Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer
D Sachdev et al.
CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer
WH Gotlieb et al.
GYNECOLOGIC ONCOLOGY (2006)
Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice
Masamitsu Yanada et al.
LEUKEMIA & LYMPHOMA (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells
GM Yanochko et al.
BREAST CANCER RESEARCH (2006)
Type I insulin-like growth factor receptor as a therapeutic target in cancer
BS Miller et al.
CANCER RESEARCH (2005)
Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)
VE Price et al.
PEDIATRIC BLOOD & CANCER (2005)
Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy
MC Heinrich et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling
C Tarn et al.
CLINICAL CANCER RESEARCH (2005)
Gastrointestinal stromal tumors in children and young adults - A clinicopathologic, molecular, and genomic study of 15 cases and review of the literature
S Prakash et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2005)
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
GS Warshamana-Greene et al.
CLINICAL CANCER RESEARCH (2005)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
S Subramanian et al.
ONCOGENE (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The insulin-like growth factor system and cancer
D LeRoith et al.
CANCER LETTERS (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Prevention of cytokine-induced apoptosis by insulin-like growth factor-I is independent of cell adhesion molecules in HT29-D4 colon carcinoma cells -: evidence for a NF-κB-dependent survival mechanism
F Garrouste et al.
CELL DEATH AND DIFFERENTIATION (2002)
DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma
G Armengol et al.
CANCER GENETICS AND CYTOGENETICS (2000)
Share Paper
